Retroviral vectors have shown their curative potential in clinical trials correcting monogenetic disorders. However, therapeutic benefits were compromised due to vector-induced dysregulation of cellular genes and leukemia development in a subset of patients. Bromodomain and extraterminal domain (BET) proteins act as cellular cofactors that tether the murine leukemia virus (MLV) pre-integration complex to host chromatin via interaction with the MLV integrase (IN) and thereby define the typical gammaretroviral integration distribution. We engineered next-generation BET-independent (Bin) MLV vectors to retarget their integration to regions where they are less likely to dysregulate nearby genes. We mutated MLV IN to uncouple BET protein interaction and fused it with chromatin-binding peptides. The addition of the CBX1 chromodomain to MLV IN W390A efficiently targeted integration away from gene regulatory elements. The retargeted vector produced at high titers and efficiently transduced CD34 + hematopoietic stem cells, while fewer colonies were detected in a serial colony-forming assay, a surrogate test for genotoxicity. Our findings underscore the potential of the engineered vectors to reduce the risk of insertional mutagenesis without compromising transduction efficiency. Ultimately, combined with other safety features in vector design, next-generation BinMLV vectors can improve the safety of gammaretroviral vectors for gene therapy.
INTRODUCTION
Stable integration of retroviral vectors encompassing a therapeutic transgene enables gene correction of severe blood and immune disorders. Over the past 25 years, murine leukemia virus (MLV)-based vectors have shown therapeutic benefit in gene therapy studies for primary immunodeficiencies (PIDs), such as X-linked severe combined immunodeficiency (SCID-X1), adenosine deaminase deficiency-severe combined immunodeficiency (ADA-SCID), and Wiskott-Aldrich syndrome (WAS). [1] [2] [3] [4] MLV-based vectors were successfully used in the first clinical trials for ADA-SCID. [5] [6] [7] This led to the recent European approval of a retrovirus-based gene therapy product (Strimvelis; GSK GlaxoSmithKline Pharmaceuticals) to treat patients that lack a suitable human leukocyte antigen (HLA)-matched related stem cell donor. 8, 9 However, in clinical trials for other PIDs, several patients developed leukemia or myelodysplasia, raising concerns about the safety of gene therapy. [10] [11] [12] [13] [14] These side effects have been directly attributed to the integration pattern and vector design. Insertional mutagenesis occurred as a consequence of vector integration preference in proximity of proto-oncogenes and activation by strong viral promoter and enhancer elements in the long terminal repeat (LTR) of retroviral vectors. To prevent insertional mutagenesis, self-inactivating (SIN) vectors with deleted enhancer sequences were designed. The lack of promoter/enhancer activity is compensated by weak heterologous promoters to drive transgene expression, such as the elongation factor 1 a short (EFS) and phosphoglycerate kinase (PGK) promoters. 15, 16 Additionally, introduction of genetic insulator sequences has improved the safety of viral vectors. [17] [18] [19] [20] [21] [22] The efficacy of these modified vectors was confirmed in pre-clinical studies and they are now in phase I/II clinical trials for several PIDs. 19, [23] [24] [25] [26] [27] A complementary approach to improve the safety of gene therapy is to alter the integration pattern, directing integration away from potentially unsafe regions. Gammaretroviral integration is not random, but rather is dictated by host cellular cofactors, such as the bromodomain and extraterminal domain (BET)-containing family of proteins (BRD2, BRD3, and BRD4) that serve as anchors on the host chromatin. 28, 29 A motif in the unstructured C-terminal tail of MLV integrase (IN) interacts with the extraterminal (ET) domain of BRDs, where the latter tethers the retroviral preintegration complex (PIC) to chromatin regions enriched in BET proteins and thereby defines the integration profile. [28] [29] [30] Deletion of the C-terminal domain (D23 amino acids [aa], IN ) or a single substitution (IN W390A ) uncouples the BET interaction, resulting in BET-independent (Bin) MLV vectors that transduce target cells at wild-type (WT) efficiency but with diminished integration in the vicinity of retroviral integration markers. 31 Here, we developed next-generation BinMLV vectors with a potentially safer integration profile and lower propensity to activate nearby genes in an effort to alleviate the risk of insertional mutagenesis by interfering with the chromatin-tethering process. We linked chromatin binding peptide sequences to the C-terminal end of BinMLV IN and demonstrated that fusion of these peptides to BinMLV IN generates vectors that produce at high titers and transduce cells at wild-type efficiency. The addition of the chromodomain of CBX1 to MLV IN_W390A efficiently retargeted integration away from gene regulatory elements. More importantly, the retargeted vector transduced human CD34 + hematopoietic stem cells (HSCs) at wild-type efficiency, while genotoxicity assays revealed reduced transformation potential.
RESULTS

Efficient Transduction and Integration of Next-Generation BinMLV Vectors
To direct BinMLV integration away from potentially unsafe chromosomal regions, we tailored the chromatin-tethering process by fusing tethering peptides (between 16 and 61 aa long) to the C-terminal end of IN W390A in the MLV packaging plasmid. We opted for peptides that bind histone markers that are widely spread across the chromatin ( Figure 1A ; Table 1 ). On one hand, we used peptides derived from cellular proteins that bind specific epigenetic histone modifications, such as the chromodomain of heterochromatin-binding protein 1b (CBX1, aa 20-73) and the chromodomain of Y-like protein (CDYL; aa 1-60), 32, 33 giving rise to IN W390A-CBX and IN W390A-CDYL , respectively. Alternatively, we fused virus-derived peptides, such as the tethering domain of the human papilloma virus (HPV8) E2 protein (aa 240-255) 34 and the N-terminal end of Kaposi sarcoma's latency associated nuclear antigen (LANA; aa 1-31), which bind to core histone 2A and 2B, 35 resulting in IN W390A-E2 and IN W390A-LANA , respectively.
The respective packaging plasmids were subsequently used to produce vesicular stomatitis virus glycoprotein G (VSV-G) pseudotyped MLV-based vectors encoding an LTR-driven EGFP reporter (MLV IN_W390A-CBX , MLV IN_W390A-CDYL , MLV IN_W390A-E2 , and MLV IN_W390A-LANA ; Figure 1A ). In line with previous results, 31 transduction efficiencies in SupT1 cells were at similar levels for MLV IN _ W390A and MLV IN _ WT ( Figure 1B ). The addition of peptide sequences to the C-terminal end of MLV IN_W390A resulted in BinMLV vectors that transduced as efficiently as MLV IN _ WT at different MOIs ( Figure 1B ) and resulted in comparable expression levels (measured as mean fluorescence intensities [MFIs] at day 3; Figure 1C ). Transduction efficiencies and MFIs were corroborated at 10 days post-transduction, underscoring stable expression for the respective integrated vectors (Figures S1A and S1B). Similar data were obtained following transduction of HeLa cells (data not shown). Collectively, these results indicate that the addition of peptide se-quences at the C-terminal end of MLV IN_W390A does not impair vector integrity nor transduction efficiency compared to MLV IN Figure 2A ; Table S1A ). For comparison, integration datasets of prototype foamy viral vectors (FVs 36 ) and HIV-derived lentiviral vectors (LVs 37 ) were juxtaposed ( Figure 2A ). FVs are known to have a lower tendency to integrate near promoter regions compared to MLV vectors. 36 MLV IN_W390A integration near TSSs was comparable to that of FVs (10.17% and 10.3%, respectively), whereas MLV IN_W390A-CBX and MLV IN_W390A-LANA integration occurred $2-fold less near TSSs ( Figure 2A ; Table S1A ) yet more frequently than LVs. 37 Similar results were obtained for larger window sizes (4-kb window, data not shown). Together, the data confirm that fusion of the CBX1 chromodomain and LANA peptide to MLV IN shifts vector integration away from the traditional markers associated with MLV integration.
In a next step, we analyzed integration preferences relative to a wider set of genomic features to evaluate overall vector integration (represented by heatmaps, Figure 2B ). The tile color depicts the correlation for an integration dataset with the respective genomic feature On the other hand, MLV IN_W390A-LANA only showed significant effects in smaller window sizes for the typical determinants of MLV vector integration, such as TSSs, CpG islands, and DHSs.
Since some of the peptides recognize specific chromatin marks, we also analyzed integration preferences near a collection of epigenetic features ( Figure 2C ). In line with previous data, uncoupling of BET interaction (MLV IN_W390A ) yields a more random integration pattern (compare colors between MLV IN_WT and MLV IN_W390A ; tile colors shift toward black). 31 Figure 2C ). CBX1 is known to bind H3K9me2/3 epigenetic marks via its chromodomain. 32 Interestingly, MLV IN_W390A-CBX shifts integration more into transcriptionally silent heterochromatin regions, which is generally disfavored for integration, marked by di-and/or tri-methylation of H3K9 and H3K27 (p < 0.001, compared to MLV IN_W390A ; yellow tiles are darker). Together, these data show that the fusion of peptide tethers to the C-terminal end of MLV IN W390A effectively retargets integration. As integration is shifted away from traditional MLV integration markers, known to associate with insertional mutagenesis in gene therapeutic trials, 39 a potentially safer integration site profile might be obtained.
Addition of Small Peptides to MLV IN_1-380 Rescues Its Transduction Defect
Apart from W390A substitution, deletion of the C-terminal tail of MLV IN (D23 aa, IN 1-380 ) similarly detargeted MLV integration, but with a transduction efficiency for MLV IN_1-380 that was $3-fold lower than for MLV IN_WT . 31 Therefore, we fused the respective peptides as an alternative C-terminal tail to IN 1-380 to assess whether transduction efficiency could be improved (MLV IN_1- Next, we amplified 28,607 unique integration sites (Table S1B) to evaluate whether these IN chimeras also redistributed vector integration. In line with earlier data, MLV IN_1-380 integration was decreased near TSSs, CpG islands, and DHSs compared to MLV IN_WT 31 ( Figure S2A ; Table S1B ). Fusion of CDYL or E2 peptides to MLV IN_1-380 did not alter integration site distribution, whereas fusion of the CBX1 chromodomain and LANA peptide redistributed integration sites in a similar fashion as for the MLV IN_W390A fusions (compare Figures 2A and S2A ; compare Tables S1A and S1B). Additionally, MLV IN_1-380-CBX integration redistributed similar to MLV IN_W390A-CBX for a wide range of genomic features ( Figure S2B 
Addition of Peptide Tethers Does Not Alter the Local MLV Integration Site Sequence
Retroviral INs show weak but discernable target sequence preferences surrounding the site of integration. This local integration site sequence is mainly determined by IN contacts with the (nucleosomal) DNA template. 40, 41 To assess whether the addition of alternative peptide tethers to MLV IN_W390A influenced the local integration site sequence, we constructed sequence logos ( Figure S3 ). Results indicate that the local integration site sequence preferences remained unaffected. 42 Figure 4D ) and no difference in MFIs could be observed (Table S3 ) for the different BinMLV vectors, confirming the lack of increased transgene silencing.
Reduced Transformation Potential of Next-Generation BinMLV IN_W390A-CBX Vector
The intrinsic integration preference of MLV-based vectors has been shown previously to be one of the driving factors of vector-mediated genotoxicity that occurred when the integrated vector dysregulated host genes, leading to oncogenic transformation. Therefore, we evaluated the genotoxic potential of next-generation BinMLV vectors carrying a MLV.SIN-vector genome with an internal SF enhancer/ promoter, which is known to trigger insertional transformation events 21, 45 ( Figure S4A ) in the in vitro immortalization assay (IVIM) 46 and the transformational incidence in a murine CFU assay ( Figure S4B ). 47, 48 To ensure the chance of immortalization, at least 55% of cells were transduced, corresponding to a mean vector copy number (VCN) of > 2. 49 Murine hematopoietic lineage-depleted (lin À ) bone marrow cells were transduced with the indicated vectors at different MOIs in six independent transductions in three IVIM assays ( Figure S4C ). Transduction efficiencies and integrated VCNs were comparable for the different vectors ( Figures 5A and 5B) . The IVIM assay revealed immortalization for all MLV vectors carrying the MLV.SIN.SF vector architecture ( Figures 5C and S4C) . The replating frequency is a measure for the fitness of clones, while the number of positive assays reflects the incidence of immortalization events. MLV.SIN.SF IN_W390A The serial replating CFU assay is a method used to confirm cellular anchorage-independent growth in vitro. The assay provides a stringent method for the detection of the tumorigenic potential of transformed murine HSCs in semi-solid medium. 47, 48 In a parallel approach, we sought to assess the serial colony-forming capacity of the transduced lineage marker-negative cells 2 weeks after expansion in the IVIM assay. We included cells transduced with an LTR-driven MLV-based vector as an additional positive control. 46 Cells were plated at a density of 5,000 cells/well in semi-solid medium (Figure S4B ). After 10 days in culture (first round, Figures 5D and  S4B ), the number of colonies obtained for all MLV.SIN.SF vectors was not significantly different from that of non-transduced cells (p > 0.05, compared to negative control, Mann-Whitney U test, Figure 5D ), whereas the number of colonies for the positive control was significantly higher (p < 0.05, compared to negative control, Mann-Whitney U test, Figure 5D ). After isolating the cells from the colony assays, 5,000 cells were replated (second round, Figures 
DISCUSSION
Retroviral vector technology offers great potential to treat genetic disorders and is a powerful tool for long-term correction of genetic defects in a variety of severe hematological disorders. 1, 50, 51 Despite the www.moleculartherapy.org initial success, a subset of patients developed serious adverse events, such as leukemia or myelodysplasia, that could be directly related to the design and characteristics of the viral vector used. [10] [11] [12] [13] [14] Understanding the mechanisms of retroviral vector genotoxicity is, therefore, essential to engineer improved viral vectors with reduced genotoxic potential.
Vector-mediated genotoxicity is defined by (1) the specific integration profile and (2) the design of the integrating proviral genome. Each retroviral family displays a specific integration profile. MLV integration is significantly enriched near TSSs and active enhancer regions 38 and thus potentially causes insertional mutagenesis. Significant efforts have been made to develop next generations of retroviral vectors with reduced genotoxic potential, such as SIN vectors and weaker internal promoters. 19, 21, [52] [53] [54] [55] [56] [57] [58] Nonetheless, their integration is still targeted to gene regulatory regions, 38, 59 where they have the potential to disrupt or dysregulate the transcription of nearby genes by other mechanisms. 60 Thus, the development of viral vectors that integrate away from genes may be safer for clinical applications. One approach is the development of other viral vector platforms with more favorable genomic distributions, like lentiviral, foamy, and alpharetroviral vectors. 25, [60] [61] [62] Alternatively, retroviral vectors can be re-engineered to obtain a more desirable integration pattern that is detargeted from its traditional chromosomal locations and ultimately only occurs at the preferred sites of the host-cell chromosome.
Retroviral integration site selection is dictated by the interaction between the viral IN as part of the PIC and cellular cofactors. Previously, we re-engineered the MLV-and HIV-cellular tethering cofactors (BET and LEDGF/p75, respectively) and demonstrated efficient redistribution of retroviral integration without compromising transgene expression. 29, [63] [64] [65] However, this approach requires the introduction (at least transient) of artificial anchors in target cells prior to application of the therapeutic vectors, 63, 64 which is not always desirable in a clinical setting. A more straightforward strategy is to directly engineer vector particles to contain proteins with adapted or unique binding domains to direct integration. Other groups attempted to redistribute MLV integration through modifications of the MLV Gag protein by fusion of tethering peptides to rescue a mutated MLV p12 protein. 66, 67 However, integration site distribution of the engineered MLV p12 chimeras was not altered, 66, 67 suggesting that the primary role of MLV p12 is tethering the virus/vector to the condensed host-cell chromatin rather than targeting the genomic integration (reviewed in Rein 68 Here, we successfully modified the MLV integration profile by fusing alternative chromatin binding peptides to BinMLV IN, resulting in a significantly different integration site pattern (Figure 2 ). The addition of the CBX1 chromodomain or LANA peptide redistributed MLV integration to the same extent relative to the typical MLV markers (TSSs, DHSs, and CpG islands), with a more than 3-fold reduction in integration frequency near TSSs and CpG islands compared to wild-type MLV (Figures 2A and S2A ; 69 where the full CBX1 protein was fused to the IN of foamy virus and additional modifications in the FV Gag protein were required to achieve significant effects on retargeting FV integration. The newly generated foamy retroviral vectors (FV) integrated $2-fold less frequent near genes and proto-oncogenes. 69 In the case of MLV, fusion of a single CBX1 chromodomain to the C-terminal end of MLV IN W390A was sufficient to shift integration toward epigenetic markers for transcriptionally silent regions (H3K9me2/3 and H3K27me3), known to be bound by CBX1 32 (Figure 2C ; Table S1 ).
Next to the retargeting effect, next-generation BinMLV vectors can be produced at high titers and efficiently transduce clinically relevant cells such as primary CD4 + T cells and CD34 + HSCs without any apparent transgene silencing (Figure 4 ), highlighting the translational potential of these vectors. Finally, we assessed the newly engineered Bin MLV vectors (MLV IN_W390A-CBX and MLV IN_W390A-LANA ) in the IVIM assay as well as in a murine serial replating CFU assay to predict the genotoxic profile ( Figure S4B ). 46 BinMLV and wild-type MLV-based vectors were produced carrying the same SIN gammaretroviral vector genome (MLV.SIN.SF) with an internal SF enhancer/ promoter to drive EGFP expression ( Figure S4A ), a design known to trigger insertional transformation. 21 The number of colonies per 5,000 cells plated in methylcellulose is shown. Each dot represents the number of colonies formed for an independently transduced culture. A negative control represents non-transduced lin À cells, while a positive control represents lin À cells transduced with an LTR-SFFV-driven MLV-based vector. After the first round (D), the number of colonies was scored and cells from positive assays were harvested and re-seeded at 5,000 cells for second round colony formation (E). Colony counts > 200 colonies are shown as 220. The experimental setup is shown in Figure S4B . VCN, vector copy number.
virus (SFFV) enhancer/promoter present in all vector genomes produced replating clones with similar efficiency in all cultures independent of the IN, while the low replating in two assays of MLV IN_W390A-CBX may be attributed to the detargeted integration pattern. Hence, at least for SFFV, promoter strength has a greater impact on the generation of insertional mutants than integration site preference in the IVIM assay.
To further address whether detargeted BinMLV vectors may be less genotoxic, we employed serial replating CFU assays of expanded murine HSCs 47, 48 to assess vector integration-related genotoxicity.
The murine CFU assays demonstrated that MLV.SIN.SF IN_WT and MLV.SIN.SF IN_W390A potently transformed murine HSCs, whereas fusion of the CBX1 chromodomain to MLV IN W390A (MLV.SIN. SF IN_W390A-CBX ) resulted in a significantly reduced transformational incidence (p < 0.05, Figure 5E ).
In conclusion, we demonstrate the potential to engineer MLV-based vectors that detarget from unsafe regions by fusing peptide fragments to the C-terminal end of MLV IN. The mere addition of the CBX1 chromodomain (and LANA peptide, to a lesser extent) was sufficient to detarget integration preference away from the traditional markers of MLV integration. In order to translate these findings into suitable vectors for the (pre)clinical field, the performance of the new Bin MLV should be evaluated in more relevant pre-clinical safety assays and bone marrow/HSC transplantation assays to validate their improved safety profile. Together, our findings will help achieve better control of MLV-based vector integration preferences. Combining next-generation BinMLV packaging constructs with next-generation SIN gammaretroviral vector architectures that incorporate a weaker physiological promoter less likely to dysregulate nearby genes 19, 70 will lead to an additional reduction in genotoxicity.
MATERIALS AND METHODS
Plasmids
BinMLV IN was cloned as previously described. 31 Chromodomians of CBX and CDYL fusions were cloned with gBlocks (IDT) in PacIand NotI-digested pcDNA3.MLV.gp packaging plasmid, a kind gift from Prof. Axel Schambach. 71 HPV8 E2 and LANA peptide fusions were introduced into the indicated vectors by an oligonucleotide annealing strategy using the same restriction sites. Oligonucleotide sequences are listed in Table S4 . All enzymes were purchased from Thermo Fisher Scientific. The integrity of all plasmids was verified by DNA sequencing.
Cell Culture
SupT1 cells were cultured in RPMI-1640 medium (Gibco-BRL/ Life Technologies) supplemented with 10% heat-inactivated fetal bovine serum (Gibco-BRL) and gentamicin (50 mg/mL; Gibco-BRL). HeLa cells were cultured in DMEM (Gibco-BRL) supplemented with 8% heat-inactivated fetal bovine serum and gentamicin. All cells were grown in a humidified atmosphere with 5% CO 2 at 37 C.
Primary Cell Purification
Human peripheral blood mononuclear cells (PBMCs) were purified from buffy coats of three different donors, obtained from the Red Cross blood transfusion center, using density-gradient centrifugation (Lymphoprep; Axis-Shield). Primary CD4 + T cells were selectively enriched using bi-specific monoclonal antibody (mAb) CD3.8 (0.5 mg/mL, NIH AIDS Reagents Program; https://www.aidsreagent. org) for 5 days. CD4 + T cells were cultured in RPMI medium supplemented with 15% FBS, gentamycin, interleukin (IL)-2 (100 U/mL; Peprotech), and MEM Non-Essential Amino Acids Solution (MEM NEAA) (50 mg/mL; Gibco-BRL), referred to as T-cell medium (TCM). CD34 + HSCs were positively selected with anti-CD34-conjugated microbeads according to the manufacturer's instructions (MACS; Miltenyi Biotec) and stimulated for 48 hr in StemSpan SFEMII medium containing CC100 Cytokine Cocktail (STEMCELL Technologies).
Retroviral Vector Production and Transduction
Viral vectors were produced as previously described. 72 Briefly, MLVbased vectors were produced by a triple polyethylenimine (PEI)based or Ca-phosphate transfection of 293T cells with a pVSV-G envelope, pcDNA3.MLV.gp packaging plasmids or their derived fusions (see above), and p450-GFP transfer plasmid (kindly provided by F.D. Bushman) encoding an LTR-driven EGFP reporter. For the IVIM assay, the transfer plasmid pSRS11.SF.GFP.pre (referred to here as MLV.SIN.SF.EGFP.pre) was used, which was kindly provided by Axel Schambach. 71 Produced vectors were concentrated by tangential flow filtration and normalized based on RT units (RTUs; non-functional titration) by the SYBR Green I product-enhanced reverse transcriptase assay (SG-PERT). 73 Subsequently, functional transducing titers were determined in SupT1 cells reaching titers > 10 7 TU/mL. For transduction of laboratory cell lines, SupT1 cells (12 Â 10 4 /well) and HeLa cells (2 Â 10 4 /well) were seeded in 96-well plates and transduced with a MOI of 1 and 3 of the respective vectors.
Seventy-two hours post-transduction, 50% of the cells were harvested for FACS analysis, while the remaining 50% were cultured for 10 days post-transduction for a second FACS analysis and to perform integration site sequencing. Prior to primary cell transduction, CD4 + T cells (25.104/well) and CD34 + HSCs (10.104/well) were pre-stimulated for 5 days in TCM and 2 days in StemSpan medium enriched with CC100 Cytokine Cocktail, respectively. An MOI of 4.5 of the different vectors was applied by spinoculation (2 hr, 1,200 g). Cells were analyzed for EGFP expression by flow cytometry at the indicated time points.
Genomic DNA Isolation and qPCR
Genomic DNA (gDNA) isolation and qPCR were performed as previously described. 31 Briefly, 2 million cells were pelleted and genomic DNA was extracted using a Mammalian Genomic DNA Miniprep Kit (Sigma-Aldrich). Samples corresponding to 700 ng genomic DNA were used for analysis. Each reaction contained 12.5 mL iQ Supermix (Bio-Rad), 40 nM forward and reverse EGFP primer, and 40 nM EGFP probe in a final volume of 25 mL. RNaseP or b-actin was quantified as the endogenous control (TaqMan RNaseP control reagent; Applied Biosystems). Samples were run in triplicate for 3 min at 95 C followed by 50 cycles of 10 s at 95 C and 30 s at 55 C in a LightCycler 480 (Roche Applied Science). Analysis was performed using the LightCycler 480 software supplied by the manufacturer.
Recovery of Integration Sites and Analysis of Integration Site Distributions
Recovery of integration sites was performed as previously described. 29 Briefly, linkers were ligated to restriction enzyme-digested (MseI) genomic DNA isolated from transduced cells and virus-host DNA junctions were amplified by nested PCR. Samples were individually barcoded with the second pair of PCR primers to generate 454 libraries. PCR products were purified and sequenced using 454/Roche pyrosequencing (titanium technology). Reads were quality-filtered by requiring perfect matches to the LTR linker, barcode, and flanking LTR and were subsequently mapped to the human/mouse genome. All sites were required to align to the reference genome within 3 bp of the LTR edge. To control for possible biases in the datasets due to the choice of the MseI restriction endonuclease in cloning integration sites, random control sites were generated computationally and matched to experimental sites with respect to the distance to the nearest MseI cleavage site (MRC). 74, 75 To do so, each experimental integration site was paired with three random control sites in the genome with respect to the distance to the nearest MseI cleavage site in the genome. A more detailed explanation can be found in the supplemental guidelines included in Ocwieja et al. 76 Analyses were carried out as described in Marshall et al. 77 A detailed account of the statistical methods used and the methods for forming and analyzing heatmaps using ROC curves can be found in Brady et al. 78 Consensus sequence analysis at the point of integration was performed using WebLogo3 (http://140.114.98.75/weblogo/). For association with specific genomic features, the distance of each integration site (in kilobases) to the respective genomic feature was calculated (midpoint of the CpG island or DHS, and the X5end of genes as a measure for the TSS). Integration sites upstream of the genomic feature were given negative kilobase values, while downstream integration sites were calculated as positive. For heatmaps, comparisons were carried out over three different interval sizes surrounding each integration site (5 kb, 10 kb, and 50 kb), since previous studies have shown that the interval sizes chosen for comparison can influence the conclusions. In this study, results were in line for each interval size examined (data not shown). Only the data for the 10-kb interval are shown. In the heatmap, the distribution of experimental MLV sites is normalized to that of the MRC sites, as a control for recovery bias due to cleavage by restriction enzymes (in our case, MseI). 74, 75 Results of statistical tests comparing the distributions of integration sites to the reference dataset are summarized as asterisks on each tile of the heatmap. Datasets used in the safe harbor analysis were retrieved from the Ensembl and/or UCSC databases (TxDB knownGenes, miRNA biotype, UCR; hg19) using BioMart. 79 The AllOnco list was used for oncogenes as published in Sadelain Analysis was performed according to the parameters defined in Papapetrou.
CD34 + HSC CFU Assay
For human CD34 + HSC CFU assays, freshly purified cells were seeded at 5,000 cells/well in human methylcellulose medium (methocult H4230; STEMCELL Technologies) supplemented with CC100 Cytokine Cocktail. Cells were plated in 35-mm petri dishes and cultured in a fully humidified atmosphere with 5% CO 2 at 37 C for 14 days. The number of colonies was scored after 14 days. For FACS analysis of the CFUs, colonies were harvested, washed twice with PBS, and evaluated for EGFP expression.
IVIM Assay
The IVIM assay was performed as described earlier. 46 Briefly, murine lineage marker-negative bone marrow cells were isolated from the tibias and femurs of C57BL/6 mice and enriched for stem and progenitor cells (mouse lineage cell depletion kit; Miltenyi Biotec) and frozen in aliquots. After thawing and 48 hr of prestimulation, 1 Â 10 5 lin À cells were transduced on 2 consecutive days on RetroNectin-coated (Takara; Clontech) wells with a MOI of 5, 10, or 20. TE was analyzed by flow cytometry 4 days thereafter. Cells were expanded for 2 weeks in IMDM, 10% FCS, 1 mM glutamine, 1% (v/v) penicillin/streptomycin, murine stem cell factor (mSCF) (50 ng/mL), human FMS-like tyrosine kinase 3 ligand (hFlt3L) (100 ng/mL), murine IL (mIL)-3 (20 ng/mL), and human IL (hIL)-11 (100 ng/mL; all cytokines purchased from Peprotech) and diluted to a cell density of 500,000 cells/mL approximately twice a week. Cells were the seeded on 96-well suspension plates at a density of 100 cells per well (48 wells seeded from each culture). Replating clones were detected by microscopic scoring. The replating frequency (according to Poisson distribution) was calculated with L-calc (STEMCELL Technologies) and normalized by VCN as determined 5 days post-transduction.
Murine Serial CFU Assay
Murine lineage marker-negative bone marrow (BM) cells were purified and transduced as in the IVIM assay. After 2 weeks of expansion, cells were plated (5,000 cells/well) in methylcellulose (HSC006; R&D Systems) supplemented with 20 ng/mL interleukin-3, and 50 ng/mL murine stem cell factor. The number of colonies was scored after 10 days. For serial replating, colonies were harvested and replated in fresh methylcellulose medium at the same density of 5,000 cells/ well for the subsequent round. 
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